CARGO Therapeutics (NASDAQ:CRGX – Get Free Report) announced its quarterly earnings data on Tuesday. The company reported ($0.88) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.14) by $0.26, Zacks reports.
CARGO Therapeutics Stock Performance
Shares of CARGO Therapeutics stock traded down $0.86 during midday trading on Thursday, reaching $18.17. 46,518 shares of the company’s stock traded hands, compared to its average volume of 255,601. The company has a market cap of $834.00 million and a PE ratio of -4.18. The stock has a 50 day moving average of $20.69 and a 200-day moving average of $18.63. CARGO Therapeutics has a 12 month low of $13.56 and a 12 month high of $33.92.
Insider Buying and Selling at CARGO Therapeutics
In other CARGO Therapeutics news, CEO Gina Chapman sold 2,975 shares of the firm’s stock in a transaction dated Thursday, September 19th. The shares were sold at an average price of $25.03, for a total value of $74,464.25. Following the completion of the sale, the chief executive officer now directly owns 103,905 shares in the company, valued at $2,600,742.15. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. In other news, CFO Anup Radhakrishnan sold 1,600 shares of the firm’s stock in a transaction on Wednesday, September 18th. The stock was sold at an average price of $25.28, for a total transaction of $40,448.00. Following the completion of the transaction, the chief financial officer now directly owns 6,446 shares in the company, valued at $162,954.88. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Gina Chapman sold 2,975 shares of the company’s stock in a transaction dated Thursday, September 19th. The stock was sold at an average price of $25.03, for a total transaction of $74,464.25. Following the completion of the transaction, the chief executive officer now owns 103,905 shares in the company, valued at approximately $2,600,742.15. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders own 1.38% of the company’s stock.
Wall Street Analysts Forecast Growth
Check Out Our Latest Stock Analysis on CRGX
CARGO Therapeutics Company Profile
CARGO Therapeutics, Inc, a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies.
Read More
- Five stocks we like better than CARGO Therapeutics
- What is the NASDAQ Stock Exchange?
- 3 GARP Stocks Offering Strong Growth: Aptiv, Allstate, Barrick
- Investing in Travel Stocks Benefits
- Mouse Rising: The Iger Investment Pays Off for Disney Investors
- 3 REITs to Buy and Hold for the Long Term
- Can CAVA Stock Be the Next Chipotle? Earnings Can Help
Receive News & Ratings for CARGO Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CARGO Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.